IGF-1 LR3 (1 mg Vial) Dosage Protocol
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 with extended half-life (~6 hours vs ~12 minutes for native IGF-1) due to substitution at position 3 (Glu→Arg) and an N-terminal 13-amino-acid extension.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: Once daily | Half-life: ~6 hours
Standard Approach (3 mL = 0.33 mg/mL)
Reconstituting with 3 mL bacteriostatic water produces a concentration of 0.33 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 20 mcg | 6.0 units | 0.060 mL | 50 doses |
| Weeks 3–4 | 40 mcg | 12.0 units | 0.12 mL | 25 doses |
| Weeks 5–8 (target) | 50 mcg | 15.0 units | 0.15 mL | 20 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 30 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 40 mcg per dose, once daily (7 doses/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| IGF-1 LR3 (1 mg) vials | 3 vials | 4 vials |
| Insulin syringes (U-100) | 56 | 84 |
| Bacteriostatic water (10 mL) | 1 × 10 mL | 2 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
IGF-1 LR3 produces direct anabolic signaling without going through the GH→IGF-1 conversion pathway. This makes effects faster than HGH (days vs weeks) but with hypoglycemia risk that requires careful management.
Most research uses short cycles (4–6 weeks) due to receptor downregulation concerns and the metabolic burden of sustained supraphysiologic IGF-1.
Dosing Protocol
Daily dosing:
- Light (20 mcg/day): Conservative starting dose.
- Standard (40 mcg/day): Common research dose.
- Higher (80 mcg/day): Advanced research; significantly increased hypoglycemia risk.
Cycle structure: 4–6 weeks active, then 4–6 week break. Long-term continuous use risks receptor downregulation.
Critical timing: Eat carbohydrates within 30 minutes of dosing to manage hypoglycemia risk. Post-workout timing leverages the anabolic window.
Bloodwork cadence: Fasting glucose checks if cycling at higher doses.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
IGF-1 LR3 is a 83-amino-acid analog of IGF-1 with an arginine substitution at position 3 (reducing IGFBP binding) and an N-terminal 13-amino-acid extension. Both modifications extend half-life and increase free IGF-1 bioactivity.
It binds the IGF-1 receptor producing tyrosine kinase signaling that drives cellular proliferation, protein synthesis, and inhibition of apoptosis. Effects include skeletal muscle hypertrophy, hyperplasia, and metabolic shifts.
Potential Benefits & Side Effects
Potential Benefits
- Promotes skeletal muscle hypertrophy in animal and human studies.
- Anabolic effects more rapid than HGH due to direct IGF-1R activation.
- Studied in muscle-wasting conditions.
- Reduced binding to IGFBPs increases bioavailability.
Side Effect Profile
- Hypoglycemia risk — IGF-1 has insulin-like glucose-lowering effects.
- Joint pain in some users.
- Theoretical malignancy promotion concerns at supraphysiologic IGF-1.
- Tissue overgrowth at very high doses.
Lifestyle Factors
- Eat carbohydrate within 30 minutes of dosing to manage hypoglycemia risk.
- Resistance training maximizes anabolic outcomes.
- Monitor blood glucose, especially when starting.
- Adequate protein supports protein-synthesis substrate availability.
Injection Technique
- Subcutaneous into abdomen or thigh, or intramuscular near target muscle.
- Rotate injection sites daily.
- 90° angle with short insulin needle.